Program
ABO1108
A development code.
Its studies are mostly in Chickenpox, led by Suzhou Abogen Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Abogen Biosciences | 33 open or running | phase 3since Sep 8, 2026 | Dec 3, 2025 | Oct 17, 2027phase 3 · NCT07817108 |
Also a collaborator on its studies: abogen-biosciences-shanghai-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2025First study: phase 2 study in ChickenpoxFirst studyNCT07285278 · 300 enrolled · China
- Dec 3, 2025Phase 1 study in ChickenpoxNCT07285265 · 180 enrolled · China
- Sep 8, 2026Phase 3 study in ChickenpoxPhase 3 reachedNCT07817108 · 18,000 planned · China
Ahead
- Oct 17, 2027Primary completion: phase 3 study in ChickenpoxNCT07817108
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07817108Chickenpox · China | 3 | Recruiting | Oct 17, 2027 | 18,000 |
| NCT07285278Chickenpox · China | 2 | Active, not recruiting | Mar 9, 2026 | 300 |
| NCT07285265Chickenpox · China | 1 | Active, not recruiting | Nov 6, 2025 | 180 |
How it is read
Names in the registry
- “ABO1108”, 3 entries
Codes read as this program: ABO1108.
Conditions, from the studies’ own filings
- Chickenpox, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.